Corino Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: New York NY United States (2016)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03633591
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Corino Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

tolcapone (tasmar) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloidosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1